20026

Effects of Galium aparine Extract on the Angiogenic Cytokines and ERK1/2 Proteins in Human Breast Cancer Cells

Tumor angiogenesis is a multiple step process regulated by a range of pro- and anti-angiogenic factors, cytokines and several signaling cascades, including the ERK1/2 MAP kinase pathway. Galium aparine (GA) is a perennial plant of the family Rubiaceae, growing widespread in Anatolia. It has been shown that GA methanol (MeOH) extract has anti-proliferative and apoptotic effects on human breast cancer cells. To investigate the underlying mechanisms that might account for the anti-proliferative effect of GA extract, changes in angiogenic cytokines and ERK1 and ERK2 proteins were investigated in human MCF-7 and MDA-MB-231 breast cancer cells. Viability of breast cancer cells after treatment of GA were determined by Cell Proliferation Kit II. Changes in angiogenic cytokines in breast cancer cells was done by a Human Angiogenesis Antibody Array. Protein levels of phospho ERK1 and ERK2 were evaluated by western blot analysis. GA induced cytotoxicity and apoptosis in a time- and concentration-dependent manner in both cancer cells. Dipeptidyl peptidase-4 (DPPIV), insulin-like growth factor-binding protein 1 (IBP-1) and transforming growth factor beta 1 (TGF-β1) levels were significantly decreased; however, secretion of serpin E1 was significantly increased by GA extract in MCF-7 cells. In MDA-MB-231 cells, the levels of amphiregulin (AR), interleukin 8 (IL-8), insulin-like growth factor-binding protein 3 (IBP-3), metalloproteinase-8 (MMP-8), heparin-binding EGF-like growth factor (HB-EGF) and platelet-derived growth factor (PDGF) were decreased by GA extract treatment. The secretion of pro-angiogenic cytokines such as neuregulin-1 (NRG1-β1), vascular endothelial growth factor (VEGF) and tissue factor (TF) were significantly decreased by GA treatment in both breast cancer cells. There was also a significant decrease in protein levels of both phospho ERK1 and ERK2 in MCF-7 and MDA-MB-231 breast cancer cells by GA treatment. These data implies that GA contains potential anti-tumor and anti-angiogenic components for breast cancer cells

PDF

___

[1] Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136, E359-386.
[2] Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971; 285, 1182.
[3] Filho, A.L.; Lopes, J.M.; Schmitt, F.C. Angiogenesis and breast cancer. J. Oncol. 2010; 576384.
[4] Tuorkey, M.J. Cancer therapy with phytochemicals: present and future perspectives. Biomed. Environ. Sci. 2015; 28, 808-819.
[5] Veeresham, C. Natural products derived from plants as a source of drugs. J Adv Pharm Technol Res. 2012; 3, 200-201.
[6] Baytop, T. Therapy with Medicinal Plants in Turkey (Past and Present). Istanbul University Publications, No.:3255, Istanbul, 1984; p: 419.
[7] Orhan, N.; Deliorman, Orhan, D.; Aslan, M.; Süküroğlu, M.; Orhan, I.E. UPLC-TOF-MS analysis of Galium spurium towards its neuroprotective and anticonvulsant activities. J. Ethnopharmacol. 2012; 141, 220-227.
[8] Ergun, F.; Deliorman, D.; Velioglu, A.; Sener, B. Antimicrobial activities of Galium species. GUEDE. J. Fac. Pharm. Gazi. 1999; 16, 7-11.
[9] Hartwell, J.L., Plants Used Against Cancer: a Survey. 34. Quarterman Publications, Lloydia, 1971, pp: 386-425.
[10] Bokhari, J.; Khan, M.R.; Shabbir, M.; Rashid, U.; Jan, S.; Zai, J.A. Evaluation of diverse antioxidant activities of Galium aparine. Spectrochim. Acta A: Mol. Biomol. Spectrosc. 2013; 102, 24-29.
[11] Atmaca, H.; Bozkurt, E.; Cittan, M.; Dilek Tepe, H. Effects of Galium aparine extract on the cell viability, cell cycle and cell death in breast cancer cell lines. J. Ethnopharmacol. 2016; 186, 305-310.
[12] Karabulut, B.; Karaca, B.; Atmaca, H.; Kisim, A.; Uzunoglu, S.; Sezgin, C.; Uslu, R. Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormonerefractory prostate cancer cell lines. Mol. Biol. Rep. 2011; 38, 249-259.
[13] Esquivel-Velázquez, M.; Ostoa-Saloma, P.; PalaciosArreola, M.I.; Nava-Castro, K.E.; Castro, J.I.; MoralesMontor, J. The role of cytokines in breast cancer development and progression. J. Interferon. Cytokine. Res. 2015; 35, 1-16.
[14] Schmidt, M.; Scholz, C.J.; Gavril, G.L.; Otto, C.; Polednik, C.; Roller, J.; Hagen, R. Effect of Galium verum aqueous extract on growth, motility and gene expression in drug-sensitive and -resistant laryngeal carcinoma cell lines. Int. J. Oncol. 2014; 44, 745-760.
[15] Bauvois, B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene. 2004; 23, 317-329.
[16] Cutler MJ, Lowthers EL, Richard CL, Hajducek DM, Spagnuolo PA, Blay J. Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26. BMC Cancer. 2015 Nov 10;15:882. doi: 10.1186/s12885-015-1702-2.
[17] Erić-Nikolić, A.; Matić, I.Z.; Dorđević, M.; Milovanović, Z.; Marković, I.; Džodić, R.; Inić, M.; Srdić- Rajić, T.; Jevrić, M.; Gavrilović, D.; Cordero, O.J.; Juranić, Z.D. Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors. Immunobiology. 2011; 216, 942-946.
[18] Messmer-Blust, A.F.; Philbrick, M.J.; Guo, S.; Wu, J.; He, P.; Guo, S.; Li, J. RTEF-1 attenuates blood glucose levels by regulating insulin-like growth factor binding protein-1 in the endothelium. Circ. Res. 2012; 111, 991- 1001.
[19] Kim, K.S.; Park, J.M.; Kong, T.; Kim, C.; Bae, S.H.; Kim, H.W.; Moon, J. Retinal Angiogenesis Effects of TGF- β1 and Paracrine Factors Secreted From Human Placental Stem Cells in Response to a Pathological Environment. Cell. Transplant. 2016; 25, 1145-1157.
[20] Esquivel-Velázquez, M.; Ostoa-Saloma, P.; PalaciosArreola, M.I, Nava-Castro, K.E.; Castro, J.I.; MoralesMontor, J. The role of cytokines in breast cancer development and progression. J Interferon Cytokine. Res. 2015; 35, 1-16.
[21] Wu, J.; Strawn, T.L.; Luo, M.; Wang, L.; Li, R.; Ren, M.; Xia, J.; Zhang, Z.; Ma, W.; Luo, T.; Lawrence, D.A.; Fay, W.P. Plasminogen Activator Inhibitor-1 Inhibits Angiogenic Signaling by Uncoupling VEGF Receptor-2- αVβ3 Integrin Cross-talk. Arterioscler. Thromb. Vasc. Biol. 2015; 35, 111-120.
[22] Singer, C.F.; Hudelist, G.; Lamm, W.; Mueller, R.; Czerwenka, K.; Kubista, E. Expression of tyrosine kinases in human malignancies as potential targets for kinasespecific inhibitors. Endocr. Relat. Cancer. 2004; 11, 861- 869.
[23] Sintich, S.M.; Lamm, M.L.; Sensibar, J.A.; Lee, C. Transforming growth factor-beta1-induced proliferation of the prostate cancer cell line, TSU-Pr1: the role of platelet-derived growth factor. Endocrinology. 1999; 140, 3411-3415.
[24] Appiah-Kubi, K.; Wang, Y.; Qian, H.; Wu, M.; Yao, X.; Wu, Y.; Chen, Y. Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers. Tumour. Biol. 2016 May 19. [Epub ahead of print].
[25] Lian, C.; Ruan, L.; Shang, D.; Wu, Y.; Lu, Y.; Lü, P.; Yang, Y.; Wei, Y.; Dong, X.; Ren, D.; Chen, K.; Liu, H.; Tu, Z. Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Potent Target for Breast Cancer Therapy. Cancer. Biother. Radiopharm. 2016; 31, 85-90.
[26] McCaig, C.; Perks, C.M.; Holly, J.M. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J. Cell. Sci. 2002; 115, 4293-4303.
[27] Perks, C.M.; Bowen, S.; Gill, Z.P.; Newcomb, P.V.; Holly, J.M. Differential IGF-independent effects of insulin-like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells. J. Cell. Biochem. 1999; 75, 652-664.
[28] Clemmons, D.R.; Camacho-Hubner, C.; Coronado, E.; Osborne, C.K. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology. 1990; 127, 2679-2686.
[29] Van Lint, P.; Libert, C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine. Growth. Factor. Rev. 2006; 17, 217-223.
CBÜ Fen Bil. Dergi., Cilt 13, Sayı 1, 2017, 171-179s CBU J. of Sci., Volume 13, Issue 1, 2017, p 171-179 179
[30] Thirkettle, S.; Decock, J.; Arnold, H.; Pennington, C.J.; Jaworski, D.M.; Edwards, D.R. Matrix metalloproteinase 8 (collagenase 2) induces the expression of interleukins 6 and 8 in breast cancer cells. J. Biol. Chem. 2013; 288; 16282-16294.
[31] Ju, D.; Sun, D.; Xiu, L.; Meng, X.; Zhang, C.; Wei, P. Interleukin-8 is associated with adhesion, migration and invasion in human gastric cancer SCG-7901 cells. Med. Oncol. 2012; 29, :91-99.
[32] Waugh, D.J.; Wilson, C. The interleukin-8 pathway in cancer. Clin. Cancer. Res. 2008; 14, 6735-6741.
[33] Singh, J.K.; Farnie, G.; Bundred, N.J.; Simões, B.M.; Shergill, A.; Landberg, G.; Howell, S.J.; Clarke, R.B. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin. Cancer. Res. 2013; 19, 643-656.
[34] Cheng, L.; Zha, Z.; Lang, B.; Liu, J.; Yao, X. Heregulin-beta1promotes metastasis of breast cancer cell line SKBr-3 through upregulation of Snail and induction of epithelial-mesenchymal transition. Cancer. Lett. 2009; 280, 50-60.
[35] Yuan, G.; Qian, L.; Song, L.; Shi, M.; Li, D.; Yu, M.; Hu, M.; Shen, B.; Guo, N. Heregulin-beta promotes matrix metalloproteinase-7 expression via HER2- mediated AP-1 activation in MCF-7 cells. Mol. Cell. Biochem. 2008; 318, 73-79.
[36] Cho, S.J.; Chae, M.J.; Shin, B.K.; Kim, H.K.; Kim, A. Akt- and MAPK-mediated activation and secretion of MMP-9 into stroma in breast cancer cells upon heregulin treatment. Mol. Med. Rep. 2008; 1; 83-88.
[37] Bluff, J.E.; Brown, N.J.; Reed, M.W.; Staton, C.A. Tissue factor, angiogenesis and tumour progression. Breast. Cancer. Res. 2008; 10, 204.
[38] Arjaans, M.; Schröder, C.P.; Oosting, S.F.; Dafni, U.; Kleibeuker, J.E.; de Vries, E.G. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget. 2016; 7, 21247-21258.
[39] Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug. Discov. 2007; 6: 273.
[40] Kirsch, M.; Schackert, G.; Black, P.M. Metastasis and angiogenesis. Cancer. Treat. Res. 2004; 117, 285-304.

Celal Bayar Üniversitesi Fen Bilimleri Dergisi-Cover

ISSN: 1305-130X
Başlangıç: 2005
Yayıncı: Manisa Celal Bayar Üniversitesi Fen Bilimleri Enstitüsü

Arşiv